- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05536141
En fase 1-studie av AB521 i nyrecellekarsinom og andre solide svulster (ARC-20)
En fase 1, åpen studie, doseeskalering og doseutvidelse, for å undersøke sikkerhet, tolerabilitet og farmakokinetisk profil av AB521 monoterapi hos deltakere med klarcellet nyrecellekarsinom og andre solide svulster
The purpose of this study is to evaluate the safety and tolerability of:
- casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
- casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab or tivozanib or ivonescimab or zimberelimab and axitinib in participants with ccRCC in the dose expansion stage.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Medical Director
- Telefonnummer: +1-510-462-3330
- E-post: ClinicalTrialInquiry@arcusbio.com
Studiesteder
-
-
-
Camperdown, Australia
- Har ikke rekruttert ennå
- Research Site
-
Melbourne, Australia
- Rekruttering
- Research Site
-
Sydney, Australia
- Rekruttering
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- Rekruttering
- Research Site
-
-
California
-
San Diego, California, Forente stater, 92093
- Rekruttering
- Research Site
-
Santa Monica, California, Forente stater, 90404
- Rekruttering
- Research Site
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322-1013
- Rekruttering
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70121
- Rekruttering
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Rekruttering
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Research Site
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Rekruttering
- Research Site
-
Detroit, Michigan, Forente stater, 48201
- Rekruttering
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68124
- Rekruttering
- Research Site
-
-
New York
-
New York, New York, Forente stater, 10065
- Rekruttering
- Research Site
-
New York, New York, Forente stater, 10029
- Rekruttering
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Rekruttering
- Research Site
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- Rekruttering
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Research Site
-
Nashville, Tennessee, Forente stater, 37240
- Rekruttering
- Research Site
-
-
Texas
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Research Site
-
-
-
-
-
Barcelona, Spania
- Rekruttering
- Research Site
-
-
-
-
-
Seoul, Sør -Korea
- Rekruttering
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
Must have at least one measurable lesion per RECIST guidance
-
Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1
-
Disease-specific criteria for dose escalation:
- Participants may have any pathologically confirmed solid tumor type where no other treatment options are available
- Creatinine clearance ≥ 40 mL/min
Disease-specific criteria for dose-expansion:
- Histologically confirmed ccRCC
- Creatinine clearance ≥ 40 mL/min
Key Exclusion Criteria:
- Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product
- Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with a participant's participation in the clinical study or make the administration of investigational product hazardous
- History of trauma or major surgery within 28 days prior to the first dose of investigational product
- For all expansion cohorts: prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor (except for the tivozanib +/- casdatifan cohort). For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib. For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose Escalation Cohort 1
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Escalation Cohort 2
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Escalation Cohort 3
Participants will receive casdatifan orally twice daily |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Escalation Cohort 4
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Escalation Cohort 5
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 1
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 2
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 3
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 4
Participants will receive casdatifan orally with with cabozantinib orally |
Administered as specified in the treatment arm Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 5
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 6
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 7
Participants will receive casdatifan orally with zimberelimab infusion |
Administered as specified in the treatment arm
Andre navn:
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 8
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 9
Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion |
Administered as specified in the treatment arm
Andre navn:
Administered as specified in the treatment arm Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 10
Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion |
Administered as specified in the treatment arm
Andre navn:
Administered as specified in the treatment arm Administered as specified in the treatment arm
Andre navn:
|
|
Eksperimentell: Dose Expansion Cohort 11
Participants will receive casdatifan orally with tivozanib orally or tivozanib orally only. |
Administered as specified in the treatment arm
Andre navn:
Administered as specified in the treatment arm |
|
Eksperimentell: Dose Expansion Cohort 12
Participants will receive casdatifan orally with ivonescimab infusion. |
Administered as specified in the treatment arm
Andre navn:
Administered as specified in the treatment arm |
|
Eksperimentell: Dose Expansion Cohort 13
Participants will receive casdatifan orally with zimberelimab infusion and axitinib orally. |
Administered as specified in the treatment arm
Andre navn:
Administered as specified in the treatment arm
Andre navn:
Administered as specified in the treatment arm |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antall deltakere med dosebegrensende toksisiteter (DLT)
Tidsramme: Inntil 4 måneder
|
Inntil 4 måneder
|
|
Antall deltakere med uønskede hendelser (AE)
Tidsramme: Inntil 4 måneder
|
Inntil 4 måneder
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Objektiv responsrate målt ved responsevalueringskriterier i solide svulster (RECIST) v1.1
Tidsramme: Inntil 4 måneder
|
Inntil 4 måneder
|
|
Plasmakonsentrasjon av casdatifan
Tidsramme: Inntil 4 måneder
|
Inntil 4 måneder
|
|
Areal under plasmakonsentrasjonstidskurven (AUC) for casdatifan
Tidsramme: Inntil 4 måneder
|
Inntil 4 måneder
|
|
Maksimal observert plasmakonsentrasjon (Cmax) av kasdatifan
Tidsramme: Inntil 4 måneder
|
Inntil 4 måneder
|
|
Duration of Response as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Progression-free survival as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Overall survival
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with tivozanib
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with tivozanib
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with ivonescimab
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with ivonescimab
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Percentage of patients who are ADA-positive and ADA-negative against ivonescimab
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with zimberelimab and axitinib
Tidsramme: Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with zimberelimab and axitinib
Tidsramme: Up to 4 months
|
Up to 4 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Medical Director, Arcus Biosciences
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Urologiske neoplasmer
- Karsinom
- Karsinom, nyrecelle
- Nyre-neoplasmer
- Erytrocytose, familiær, 4
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Azoler
- Hydrokarboner
- Hydrokarboner, syklisk
- Karboksylsyrer
- Hydrokarboner, aromatisk
- Amides
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Benzenderivater
- Syrer, karbosykliske
- Benzoates
- Benzamider
- Indazoler
- Pyrazoler
- Axitinib
- Ipilimumab
- Zimberelimab
- Cabozantinib
- Tivozanib
Andre studie-ID-numre
- ARC-20
- 2024-519142-70-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Arcus will provide access to individual de-identified participant data and related study documents [e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)] upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
For more information, please visit our website.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .